Tuesday, July 9, 2024

CATEGORY

Sandoz

Biosimilars Receives Landmark Approval from European Commission

Biosimilars Wyost® and Jubbonti® have received landmark approval from the European Commission (EC), marking the first biosimilar versions of denosumab to be authorized in...

FDA Approves First Interchangeable Biosimilars for Bone Loss Management by Sandoz and Samsung Bioepis

The FDA has approved two interchangeable denosumab biosimilars in managing primary and secondary bone loss, denosumab-bddz (Wyost) and denosumab-bddz (Jubbonti), developed by Sandoz and...

A Breakthrough Biosimilar as Disease-Modifying Therapy for Multiple Sclerosis Treatment

Tyruko has been indicated as a single disease-modifying therapy (DMT) for adults diagnosed with highly active Relapsing-Remitting Multiple Sclerosis (RRMS), a designation also approved...

Novartis Has Completed The Spin-Off of Sandoz, Its Generics and Biosimilars Division

Novartis successfully carried out the Sandoz Spin-off, marking the conclusion of its strategic transformation into prominent pharmaceuticals. This separation was executed through a dividend-in-kind...

Latest news